Login / Signup

Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination.

Ana Isabel Molina-RamosElisabeth Gómez MoyanoJorge Rodríguez-CapitánMaría Angullo-GómezPatricia Gallardo-JiménezIván Pérez de PedroLucía Valiente de SantisBeatriz Pérez-VillardónIsabel Piñero-UribeJavier Mora-RoblesVíctor Manuel Becerra-MuñozManuel F Jiménez-Navarro
Published in: Journal of clinical medicine (2022)
The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
Keyphrases
  • sars cov
  • coronavirus disease
  • respiratory syndrome coronavirus
  • poor prognosis
  • public health
  • long non coding rna
  • risk factors
  • combination therapy
  • drug induced